anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a type of non-Hodgkin lymphoma first linked with breast implants in 2011. The correlation between BIA-ALCL and textured devices has led to increased use of smooth devices. However, much of the data surrounding smooth and textured devices investigates breast implants specifically and not tissue expanders.
OBJECTIVES: We performed a systematic review and a meta-analysis to compare surgical outcomes for smooth tissue expanders (STEs) and textured tissue expanders (TTEs).
METHODS: A search was performed on PubMed, including articles from 2016 to 2023 (n = 419). Studies comparing TTEs and STEs and reported complications were included. A random-effects model was utilized for meta-analysis.
RESULTS: A total of 5 articles met inclusion criteria, representing 1709 patients in the STE cohort and 1716 patients in the TTE cohort. The mean duration of tissue expansion with STEs was 221.25 days, while TTEs had a mean time of tissue expansion of 220.43 days.Our meta-analysis found no differences in all surgical outcomes except for explantation risk. STE use was associated with increased odds of explantation by over 50% compared to TTE use (odds ratio = 1.53; 95% CI = 1.15 to 2.02; P = .003).
CONCLUSIONS: Overall, STEs and TTEs had similar complication profiles. However, STEs had 1.5 times higher odds of explantation. The incidence of BIA-ALCL is low, and only a single case of BIA-ALCL has been reported with TTEs. This indicates that TTEs are safe and may lower the risk of early complications requiring explantation. Further studies are warranted to further define the relationship between tissue expanders and BIA-ALCL.
The experimental arm starts with Fluoropyrimidin/Oxaliplatin-based CRT (1.8 Gy to 45 Gy to the primary tumor and pelvic lymph nodes; followed by sequential boost of 9 Gy to the gross tumor volume) followed by consolidation chemotherapy with 6 cycles mFOLFOX6 or alternatively 4 cycles CAPOX, followed by re-staging at week 22-24. In both arms, for patients achieving a clinical complete response (cCR), as strictly assessed by clinical investigation, endoscopy and MRI, a W\&W option with close follow-up is scheduled. In case of non-complete response, immediate TME surgery is performed.
A 28-year-old woman presented with a 4-year history of fatigue and sleepiness and was found to have central hypothyroidism and mood disorder. The patient had normal thyroid volume and did not show any other pituitary axis involvement. Over the course of the disease, her symptom improvement matched with the free thyroxine (FT4) rebound and the adjustment of antipsychotic medication. The patient's grandmother had central hypothyroidism, and her mother and uncle had lowered or inappropriately normal thyroid stimulating hormone. Hence, genetic involvement was highly suspected, but whole exon sequencing did not reveal a pathogenic variant. Levothyroxine tablets were prescribed to maintain a normal median level of FT4, and mood disorder medications were adjusted by specialists. Isolated central hypothyroidism is extremely rare, and we report this case aiming to raise awareness of this condition.
The ARROW (AntiRetroviral Research fOr Watoto) protocol describes an open-label randomised trial primarily evaluating two strategic approaches for management of antiretroviral therapy (ART) in 1200 symptomatic HIV-infected infants and children initiating ART following WHO guidelines in Uganda and Zimbabwe. The first strategy compares clinically driven monitoring (CDM) with laboratory plus clinical monitoring (LCM). In both groups, tests for toxicity (standard haematology and biochemistry panels) and efficacy (lymphocyte subsets including CD4 count) will be done every 12 weeks. In LCM, all results will be returned for patient management. In CDM, physicians may request results from routine haematology/biochemistry panels if needed for clinical management, but results will not be returned routinely, and lymphocyte subsets will never be returned. Extra laboratory tests may be requested outside of the scheduled visits at any time in either group (except for lymphocyte subsets in CDM). The second strategy compares a continuous WHO-recommended first-line ART three-drug two-class regimen, comprising two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) plus one Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), with induction with four drugs (two classes) for 36 weeks followed by maintenance with three drugs. After at least 36 and 96 weeks on ART respectively, two further randomisations will assess simplification strategies which could improve long-term ART adherence (i) once versus twice daily lamivudine+abacavir NRTI drugs (ii) stopping versus continuing daily cotrimoxazole prophylaxis.
Five-stage nutrition counseling vith educational materials was carried out during hospitalization in the intensive nutrition counseling. Telephone interviews were conducted at the 2nd week and 2nd month after discharge.
Pulmonary hypertension will be excluded based on all of the following echocardiogram features: estimated systolic pulmonary artery pressure\<35mmHg and absence of right atrial or right ventricular (RV) enlargement and lack of qualitative RV dysfunction. If a subject has any of these echo features, they will be referred for right heart catheterization (RHC) and included in the appropriate group based on their RHC results.
The patients will be monitored during index hospitalization according normal practice and additionally with a bed sensor, smartphone app, and patch-holter ECG. In addition, patients will have PDL monitoring device during hospitalization. During the index hospitalization, patients will download the CardioSignal app to their own smartphone or if patient does not have a smartphone one can be provided to the patient by the study group. Patients are asked to do the first recordings at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period. When discharged home, the study subject will have the bed sensor for home-based use up to 3 months. If the average pulse rate in the bed sensor recordings have increased with 20% or the device has recorded rhythm irregularity lasting over 5 minutes (could be longer to reduce false alarms), a 12-lead ECG will be taken, and in the case of a normal ECG, a 7-day Holter monitoring is performed.
The invention provides a compound with an alpha-glucosaccharase inhibitory activity in a mulberry leaf. The preliminary screening from the mulberry leaf is carried out by immunomagnetic separation and liquid chromatography-mass spectrometry and a nuclear magnetic resonance method; and a separation or configuration target compound is prepared for verifying the alpha-glucosaccharase inhibitory activity, and thus the compound with the alpha-glucosaccharase inhibitory activity is obtained. Compared with a traditional method, no separation compound for preliminary screening is needed, so that the screening efficiency is remarkably increased, the screening time is shortened and the preparation and separation steps of the marked compound are reduced. In addition, the screening method disclosed by the invention has the characteristics of quickness, accuracy, favorable reproducibility and the like. The quick screening of the compound with the alpha-glucosaccharase inhibitory activity in a natural medicament or traditional Chinese mixture can be popularized. The compound with the alpha-glucosaccharase inhibitory activity, which is obtained by the method disclosed by the invention, can be applied to preparation of medicaments for resisting diabetes mellitus.
Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
Participants received placebo in stages. IV infusion placebo was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, a second infusion of placebo was started at 38 mL/hr for 4 hours.
BACKGROUND: Occupational health, grounded in occupational medicine, aims to enhance the well-being and labor productivity of the working population. Within this realm, there has been growing concern over the increasing instances of labor loss due to diminished physical capacity and the rise in musculoskeletal disorders. Chronic pain is also associated with musculoskeletal disorders. Another pressing issue related to chronic musculoskeletal pain was needed assistance services are underutilized, is referred to as a "service gap". Understanding trends based on age and affected regions of the body is indispensable for developing strategies to address chronic musculoskeletal pain in workers. This study aimed to elucidate age-specific trends in the prevalence and number of pain sites in chronic musculoskeletal pain as well as the patterns of treatment during chronic musculoskeletal pain, categorized by age and affected site.
METHODS: This study was conducted in December 2022 in contract to Cross Marketing Inc. The survey began on December 12, 2022 and ended on December 15, 2022. An online survey was administered to 1,946 participants (973 women and 973 men), and responses were collected, ensuring a roughly equal distribution of samples among men and women across six age groups ranging from their 20 to 70 s. The survey inquired about the presence of chronic pain in each of the eight body parts and the adoption of five different treatments when experiencing pain. Statistical analysis was performed using the chi-square test, with the measurement data categorized by age group and body part.
RESULTS: The results indicated a significantly higher prevalence of chronic pain at three or more sites among individuals in their 30 s: the prevalence of pain at each of the eight body sites varied with age. Approximately half of the participants did not engage in specific treatments during episodes of chronic pain. The presence or absence of treatment showed no significant differences according to affected site or age group. This study revealed age- and body part-related relationships with chronic musculoskeletal pain in middle-aged patients and highlighted healthcare service gaps in its management in Japan.
BACKGROUND: Enhanced recovery after surgery (ERAS) for radical distal gastrectomy needs to be improved urgently. We investigated the effects of probiotic compounds (including Lactobacillus plantarum, L. rhamnosus, L. acidophilus, and Bifidobacterium animalis subsp.lactis) on enhance recovery after gastrectomy.
METHODS: The patients in this prospective study were divided into probiotic group (PG group, n = 36) and placebo group (CG group, n = 38), taking corresponding capsule according to the protocol during the perioperative period. We compared the trends in perioperative hematologic findings and the postoperative outcomes. Patients' feces were collected for bacterial 16S rRNA sequencing. Patients were followed up at 1 month postoperatively.
RESULTS: After the application of probiotics, the patients' postoperative inflammatory response level was reduced, and the trend of postoperative NLR decrease was significantly faster in the patients of the PG group than in the CG group (P = 0.047, partial η2 = 0.054). The trend of postoperative increase in serum albumin concentration in the patients of the PG group was significantly better than that in the CG group (P = 0.016, partial η2 = 0.078). In addition, patients in the PG group met discharge criteria earlier postoperatively and had fewer medical expenses. The quality of life of PG group was improved postoperatively. Postoperative inflammation-related markers, including the ratio of Firmicutes/Bacteroidetes, were increasing in untreated patients. In addition, the postoperative microbial diversity and abundance in the PG group remained stable.
CONCLUSIONS: Probiotic compounds can reduce the inflammatory response after gastrectomy and enhance the recovery of the DGC patients by maintaining the stability of the gut microbiota.
The present invention relates to pharmaceutical compositions and is particularly concerned with pharmaceutical compositions containing N-methyl-D-aspartate (NMDA) receptor antagonists and their use in the treatment of pain. Accordingly, there is provided a pharmaceutical composition for the administration of an NMDA receptor antagonist to a human or animal subject, the composition including an NMDA receptor antagonist in an immediate release form in association with an NMDA receptor antagonist in a controlled release form. The present invention further provides a method for the therapeutic or prophylactic treatment of pain in a human or animal subject, the method including administering to the subject, a composition in accordance with the present invention. The method of the invention may be used to treat chronic or acute pain. The composition of the invention may be used in the pre-emptive treatment of pain. The NMDA receptor antagonist may be selected from a morphinan such as dextromethorphan and dextrorphan, ketamine, amantadine, memantine, eliprodil, ifenprodil, dizocilpine, remacemide, lamotrigine, riluzole, aptiganel, phencyclidine, flupirtine, celfotel, felbamate, spermine, spermidine, levemopamil, a pharmaceutically acceptable salt or ester thereof, or a metabolic precursor of any of the foregoing.
The invention discloses a traditional Chinese medicine compound treating elderly constipation. The traditional Chinese medicine compound comprises an external application preparation and an internal application preparation. The compound is characterized in that the external application preparation is prepared from large field snails, soil mirabilite, gleditsia officinalis, fistular onion stalks, fresh ginger, fermented soya beans, peppers, clover oil and saponin. The internal application preparation is prepared from sagittaria sagittifolia, ova of mantis, cynomorium, polygonatum odoratum, basella alba, water spinach, Chinese torreya, fig, fructus cannabis, semen cassiae, semen plantaginis, angelica sinensis and radix ophiopogonis. The invention further discloses a preparation method of the traditional Chinese medicine compound treating elderly constipation. Compatibility is reasonable, the mode combining external application and internal application is adopted, medicine effects are remarkably improved, and the compound can enrich and benefit essence and blood, warm and invigorate kidney yang, tonify the lung and strengthen the spleen, clear away heat and purge pathogenic fire and relax bowel, truly treats both symptoms and root causes, and achieves a remarkable treatment effect.
PURPOSE:To obtain a cosmetic for hair restoration and hair growth continuously usable without strong irritation, having excellent effects, containing an active ingredient extracted from a crude drug of Nardostachys chinensis BATALIN, Nardostachys grandiflora DC. or Prunus armeniaca L. var. ansu Maxim. with a water-insoluble organic solvent or a hydrous solvent thereof. CONSTITUTION:100g crude drug of Nardostachys chinensis BATALIN, Nardostachys grandiflora DC. or Prunus armeniaca L. var. ansu Maxim. is extracted with 1l organic solvent such as primary alcohol (e.g. methanol or butanol), acetone, THF or dioxane alone or hydrous organic solvent containing >=50wt.% the organic solvent for 2hr each time 3 times, the extracted essence is put together, filtered by suction and concentrated under reduced pressure to give viscous essence of crude drug. 0.5-5.0wt.% of the essence as an active ingredient is directly added to a base or dissolved or dispersed in a proper solvent and diluted and added as the active ingredient to the base to give a promoter for hair restoration and growth.
Medical articles in the form of strings are formed by covalently binding collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugate formulations which are extruded to make the strings. The collagen may be recombinantly produced human collagen or collagen extracted from any source, such as a bovine source or human placenta, and purified and can be of various types and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 20,000. The string can be designed to incorporate other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines. The strings contain large amounts of water when extruded and may then be dehydrated to form relatively solid but flexible strings. The strings can be injected into a living being for the purpose of providing soft tissue augmentation. Once in place, the strings rehydrate and expand in size five fold or more. Aqueous solution can be provided to enhance the rate of rehydration. The strings can also be used to suture wounds which strings can be chemically designed to dissolve in situ.
The compounds of formula Ia are prepared by reaction of an iminoether of formula II with a reactive derivative of the carboxyl group of a compound of formula III and subsequent hydrolysis in order to remove the group <IMAGE> . During the hydrolysis, certain protective groups R<7> are already split off. In the formulae, the symbols have the meaning given in Claim 1. According to another process, the compound of formula Ia is first prepared by the route shown and the protective group R<7> is then removed. The compounds obtained are useful as antibacterial medicaments. <IMAGE>   <IMAGE>   <IMAGE>
Disclosed are nanocrystals comprising metals and metal alloys, which are formed by a process that results in a layer of graphite in direct contact with the metallic core. The nanocrystals may be used in vivo as MRI contrast agents, X-ray contrast agents, near IR (NIR) heating agents, drug delivery, protein separation, catalysis etc. The nanocrystals may be further functionalized with a hydrophilic coating, e.g., phospholipid-polyethylene glycol, which improves in vivo stability. The process comprises chemical vapor deposition of metals adsorbed onto silica as a fine powder, in conjunction with a carbon containing gas, which coats the metal particles. The silica is then etched away. Preferred metals include iron, gold, cobalt, platinum, ruthenium and mixtures thereof, e.g., FeCo and AuFe. The process permits control of the alloy compositions, size, and other characteristics.
Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.
A single dose of Placebo will be administered. Supplied as 2 gelatin capsules, identical in number, size, shape and color, filled with microcrystalline cellulose.
PROBLEM TO BE SOLVED: To collect ingredients contributing to health from layer to more efficiently utilize the laver for the improvement of health than the laver itself. SOLUTION: This peptide mixture is obtained by degrading laver with pepsin and has the following natures. (A) The mixture has an average chain length of 2-5 molecules and contains at least two kinds of peptides among the following four kinds of peptides: isoleucine-tyrosine, methionine-lysine-tyrosine, leucine- arginine-tyrosine, and alanine-lysine-tryosine-serine-tyrosine. (B) Molecular weight: 200-20,000. (C) Solubility in solvents: easily soluble in water, but hardly soluble in ethanol, acetone and hexane. Since having a hypotensive action, a calcium absorption-stimulating action, an antimutagenic activity, a plasma cholesterol-reducing action, an immunopotentiative action, etc., the peptide mixture or a laver protein degradation product containing the peptide mixture can be used as a hypotensive medicine or added to a food to give a health food base on the actions.
Pain is a pervasive symptom among advanced cancer patients. In addition to pain's negative impact, unrelieved pain is linked to depression and precludes patients from dealing with other aspects of life. The World Health Organization 3-step hierarchy for pain management is effective in controlling cancer pain in 70-90% of patients. However, a significant fraction of cancer patients continue to suffer from severe pain despite high dose opioid therapy. This opioid-refractory pain requires adjunctive pain medications. Often multiple adjunctive agents are needed concurrently to optimally control opioid-refractory pain. Unfortunately, patients remain in pain during the time needed to titrate these agents, and some patients don't have this time before their death. Clinically, there exists no widely available, acute intervention to quickly control opioid-refractory pain. Intraspinal delivery of medications, peripheral nerve blocks, and neurolysis help only the subset with well-localized pain syndromes, are invasive, and require subspecialty skills. Sedation quickly relieves pain but robs a patient of the ability to interact. The hypothesis to be tested in this study is that intravenous (IV) lidocaine can acutely palliate opioid-refractory pain. IV lidocaine has been shown to be effective in small trials in non-cancer patients with conditions such as post-herpetic neuralgia and diabetic neuropathy. Additionally, there are case reports of the efficacy of IV lidocaine in cancer patients with opioid-refractory pain. However, there are no randomized, placebo-controlled trials in cancer patients establishing efficacy. Moreover, because of lidocaine's pro-arrhythmic potential and relatively narrow therapeutic window, there is a theoretical risk of harm. As a practical matter of fact, IV lidocaine is not available for the vast majority of cancer patients in the US. To illuminate this situation, a double-blind, randomized, placebo-controlled, study will be conducted to determine the efficacy of IV lidocaine in acutely relieving severe opioid-refractory pain in advanced cancer patients. Secondary end-points include analyses of safety and clinical parameters predictive of lidocaine response. The expected outcome is that lidocaine will acutely, effectively, and safely relieve opioid-refractory pain. This outcome will significantly add to the evidence-based clinical armamentarium available to treat opioid-refractory pain and will significantly improve cancer patients' quality of life.
Outcomes of Turkish adaptation of Free and cued selective reminding test (SIHT-16) is compared with memory and non-memory test in three alternative lists: a,b, and c parallel lists. The participants are assessed in neurological diagnosis routine.
Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.